UY34271A - Anticuerpos anti-tie2 y usos de los mismos - Google Patents

Anticuerpos anti-tie2 y usos de los mismos

Info

Publication number
UY34271A
UY34271A UY0001034271A UY34271A UY34271A UY 34271 A UY34271 A UY 34271A UY 0001034271 A UY0001034271 A UY 0001034271A UY 34271 A UY34271 A UY 34271A UY 34271 A UY34271 A UY 34271A
Authority
UY
Uruguay
Prior art keywords
same
tie2 antibodies
tie2
antibodies
escanear
Prior art date
Application number
UY0001034271A
Other languages
English (en)
Inventor
Thurston Gavin
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of UY34271A publication Critical patent/UY34271A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención proporciona anticuerpos que se unen a Tie2 y métodos de uso de los mismos. Según ciertas realizaciones de la invención, los anticuerpos son anticuerpos completamente humanos que se unen a Tie2 humano y bloquean la interacción 5 entre Tie2 y uno o más ligandos de Tie2, tales como angiopoyetina 1 (Ang1), angiopoyetina 2 (Ang2), angiopoyetina 3 (Ang3) y/o angiopoyetina 4 (Ang4). Los anticuerpos de la invención son útiles, entre otros, para el tratamiento de enfermedades y trastornos asociados a una o más actividades biológicas de Tie2, que incluyen la angiogénesis.
UY0001034271A 2011-08-19 2012-08-17 Anticuerpos anti-tie2 y usos de los mismos UY34271A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161525308P 2011-08-19 2011-08-19
US201261587213P 2012-01-17 2012-01-17
US201261674405P 2012-07-23 2012-07-23

Publications (1)

Publication Number Publication Date
UY34271A true UY34271A (es) 2013-02-28

Family

ID=46785799

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034271A UY34271A (es) 2011-08-19 2012-08-17 Anticuerpos anti-tie2 y usos de los mismos

Country Status (15)

Country Link
US (4) US9017670B2 (es)
EP (2) EP3415533A1 (es)
JP (2) JP6333174B2 (es)
KR (1) KR20140054303A (es)
CN (2) CN103874709B (es)
AR (1) AR087567A1 (es)
AU (1) AU2012299195B9 (es)
CA (1) CA2844306C (es)
ES (1) ES2694411T3 (es)
IL (1) IL230529A (es)
IN (1) IN2014CN02025A (es)
MX (1) MX359833B (es)
SG (1) SG10201606872TA (es)
UY (1) UY34271A (es)
WO (1) WO2013028442A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103874709B (zh) 2011-08-19 2016-12-21 瑞泽恩制药公司 抗tie2抗体及其用途
US10316105B2 (en) 2011-08-19 2019-06-11 Regeneron Pharmaceuticals, Inc. Anti-TIE2 antibodies and uses thereof
EP3062811B1 (en) * 2013-11-01 2019-04-03 Regeneron Pharmaceuticals, Inc. Angiopoietin-based interventions for treating cerebral malaria
TWI685502B (zh) * 2014-07-15 2020-02-21 日商安斯泰來製藥股份有限公司 新穎抗人類Ｔｉｅ２抗體
WO2016115092A1 (en) * 2015-01-12 2016-07-21 La Jolla Institute For Allergy And Immunology Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever
US10537637B2 (en) 2017-01-05 2020-01-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
WO2018148567A1 (en) 2017-02-09 2018-08-16 Fred Hutchinson Cancer Research Center Biomarkers and uses thereof for selecting immunotherapy intervention
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof
KR102497171B1 (ko) 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
WO2019235856A1 (ko) * 2018-06-07 2019-12-12 기초과학연구원 Tie2에 결합하는 항체 및 이의 용도
JP7390317B2 (ja) 2018-06-07 2023-12-01 インスティテュート・フォー・ベイシック・サイエンス 抗Ｔｉｅ２抗体およびその使用
CN113056285A (zh) 2018-06-29 2021-06-29 璟尚生物制药公司 抗肿瘤免疫检查点调节剂拮抗剂
JP2022540571A (ja) 2019-06-28 2022-09-16 ゲンスン バイオファーマ、インコーポレーテッド 変異したＴＧＦβ１－ＲＩＩ細胞外ドメインおよび免疫グロブリン足場で構成される抗腫瘍アンタゴニスト
SG11202111656WA (en) * 2019-08-14 2021-11-29 Pharmabcine Inc Anti-tie2 antibody and use thereof
US20210155697A1 (en) * 2019-11-21 2021-05-27 Unity Biotechnology, Inc. Antibodies directed to tie-2 and methods of use
WO2022225182A1 (ko) * 2021-04-23 2022-10-27 (주)니오테스바이오 안지오포이에틴-2에 특이적으로 결합하는 항체, 또는 이의 단편
US20220389120A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
US20230287109A1 (en) * 2022-01-13 2023-09-14 Ingenia Therapeutics Inc. VEGF and TIE2-Binding Fusion Protein and Uses Thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
WO1994000469A1 (en) 1992-06-26 1994-01-06 Immunex Corporation Novel tyrosine kinase
US5681714A (en) 1992-07-30 1997-10-28 Mount Sinai Hospital Corporation Nucleic acid encoding tek receptor tyrosine kinase
AU8143094A (en) 1993-11-12 1995-05-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. (tie-2), a novel receptor tyrosine kinase
AUPM379494A0 (en) 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - ii
US20030040463A1 (en) * 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
US6376653B1 (en) 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US6365154B1 (en) * 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
JP4587626B2 (ja) 1999-06-07 2010-11-24 イミュネックス・コーポレーション Ｔｅｋアンタゴニスト
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6824773B2 (en) * 1999-12-20 2004-11-30 Immunex Corporation TWEAK receptor
JP2003535910A (ja) 2000-06-23 2003-12-02 シエーリング アクチエンゲゼルシャフト ＶＥＧＦ／ＶＥＧＦ及びアンギオポイエチン／Ｔｉｅ受容体機能を妨げる組合せ及び組成物、並びにそれらの使用（ＩＩ）
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) * 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7485297B2 (en) 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
JP2008501677A (ja) * 2004-06-04 2008-01-24 ファイザー・プロダクツ・インク 異常な細胞増殖を治療する方法
WO2006005361A1 (en) * 2004-07-13 2006-01-19 Centre National De La Recherche Scientifique Peptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses
JP2008532476A (ja) * 2004-08-12 2008-08-21 ダイアックス コーポレーション 複合結合タンパク質
AU2006237920A1 (en) 2005-04-19 2006-10-26 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compound
DK2076290T3 (en) 2006-10-27 2017-01-23 Sunnybrook Health Sciences Center MULTIMERIC TIE 2 AGONISTS AND APPLICATIONS THEREOF IN STIMULATING ANGIOGENESIS
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US8685393B2 (en) 2008-03-24 2014-04-01 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of systemic anthrax infection
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US8980268B2 (en) * 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US20130188013A1 (en) * 2011-07-22 2013-07-25 Qualcomm Incorporated Mvc based 3dvc codec supporting inside view motion prediction (ivmp) mode
CN103874709B (zh) 2011-08-19 2016-12-21 瑞泽恩制药公司 抗tie2抗体及其用途

Also Published As

Publication number Publication date
KR20140054303A (ko) 2014-05-08
CN106963946A (zh) 2017-07-21
ES2694411T3 (es) 2018-12-20
AR087567A1 (es) 2014-04-03
AU2012299195B2 (en) 2018-04-19
CN103874709B (zh) 2016-12-21
AU2012299195A1 (en) 2014-03-13
US10023641B2 (en) 2018-07-17
US9546218B2 (en) 2017-01-17
US9017670B2 (en) 2015-04-28
JP2017186347A (ja) 2017-10-12
AU2012299195B9 (en) 2018-05-10
WO2013028442A1 (en) 2013-02-28
MX2014001738A (es) 2014-03-27
US10442864B2 (en) 2019-10-15
US20150197578A1 (en) 2015-07-16
US20130209492A1 (en) 2013-08-15
SG10201606872TA (en) 2016-10-28
US20180291105A1 (en) 2018-10-11
NZ621481A (en) 2016-04-29
US20170088622A1 (en) 2017-03-30
CN103874709A (zh) 2014-06-18
JP6333174B2 (ja) 2018-05-30
IN2014CN02025A (es) 2015-05-29
IL230529A (en) 2017-07-31
JP6654165B2 (ja) 2020-02-26
JP2014525934A (ja) 2014-10-02
EP3415533A1 (en) 2018-12-19
CA2844306A1 (en) 2013-02-28
CA2844306C (en) 2022-08-16
EP2744827A1 (en) 2014-06-25
IL230529A0 (en) 2014-03-31
EP2744827B1 (en) 2018-10-03
MX359833B (es) 2018-10-12

Similar Documents

Publication Publication Date Title
UY34271A (es) Anticuerpos anti-tie2 y usos de los mismos
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
UY34721A (es) Anticuerpos anti-hla-b*27 y usos de éstos.
UY34603A (es) Anticuerpos anti-asic-1 y usos de los mismos
UY34680A (es) Anticuerpos humanos anti-cd27, métodos, y usos
ECSP14005975A (es) Anticuerpos anti-PHF-tau y sus usos
UY34539A (es) Heteroarilos y usos de los mismos
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
TWD180147S (zh) 淨水器
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
ECSP13012786A (es) Anticuerpos anti-pcsk9 y métodos de uso
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
CL2016001432A1 (es) Nuevos anticuerpos anti-dpep3 y métodos de uso
UY34018A (es) Derivados glucósidos y usos de los mismos
UY33946A (es) Derivados de c4-monometil triterpenoides y sus métodos de uso
UY34764A (es) Derivados de 2,2-difluoropropionamida de metilo de bardoxolona, formas polimórficas y sus métodos de uso
UY34502A (es) Arilos y heteroarilos bicíclicos inhibidores de los canales de sodio
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
CL2015001266A1 (es) Anticuerpos de antihemaglutinina y métodos de uso.
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
CO6940376A2 (es) Anticuerpos anti-psgl-1 y usos de los mismos